What Rezzayo treats.
- Candidemia (Candida bloodstream infection)
- Invasive candidiasis
- Patients transitioning from inpatient daily echinocandin therapy to outpatient maintenance
The mechanism.
Rezzayo (rezafungin) is an echinocandin antifungal that inhibits fungal cell wall synthesis, killing Candida species and other invasive fungi. Unlike traditional echinocandins that require daily infusions, Rezzayo’s extended half-life allows once-weekly dosing — making outpatient treatment feasible for patients who would otherwise need extended hospitalization or daily clinic visits.
Your Rezzayo infusion experience.
Rezzayo is administered as a 1-hour IV infusion. After an initial loading dose, maintenance is once weekly for the duration of treatment, typically 14 days from the first negative blood culture. We coordinate with your prescribing infectious disease specialist on dosing and treatment duration.
Insurance & out-of-pocket cost.
Rezzayo is covered by most commercial insurance and Medicare Part B when prescribed by your physician for an FDA-approved indication. We verify your benefits before your first infusion and handle prior authorization on your behalf. Most commercially insured patients pay only their standard specialty copay — typically $20–$100 per visit. Manufacturer copay assistance programs may further reduce your cost.